Literature DB >> 17364435

Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial.

Petra Kaufmann1, Gilbero Levy, Jacquelina Montes, Richard Buchsbaum, Alexandra I Barsdorf, Vanessa Battista, Rachel Arbing, Paul H Gordon, Hiroshi Mitsumoto, Bruce Levin, John L P Thompson.   

Abstract

We wished to determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) is reliable when used as primary outcome measure in a multicenter clinical trial. To establish inter-rater reliability, we randomly assigned 19 primary raters and 11 back-up raters to score nine amyotrophic lateral sclerosis (ALS) patients using the ALSFRS-R. To assess intra-rater reliability and reliability of telephone administration, we randomly assigned consecutive participants of the Clinical Trial of High Dose Coenzyme Q10 in ALS (QALS) to have in-person ALSFRS-R interviews at both screening and baseline visits (n=41 patients) or to have the ALSFRS-R interview by telephone at screening and in person at the baseline visit (n=27). An intraclass correlation coefficient (ICC) of reliability was calculated using a one-way random effects analysis of variance model. In the inter-rater reliability assessment, the primary raters performed 54 ratings on nine patients with ICC=0.93 (95% CI 0.84-0.98). For back-up raters, 32 ratings on nine patients resulted in ICC=0.93 (95% CI 0.82-0.98). The intra-rater reliability for in-person interviews was ICC = 0.95 (95% CI 0.92-0.98). The reliability of telephone administration compared to in-person interviews was ICC=0.97 (95% CI 0.93-0.98). We conclude that the ALSFRS-R shows excellent inter- and intra-rater reliability, and reliability of telephone administration when used as primary outcome measure in a multicenter ALS trial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364435     DOI: 10.1080/17482960600888156

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  36 in total

1.  Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study.

Authors:  Christina Schuster; Elisabeth Kasper; Judith Machts; Daniel Bittner; Jörn Kaufmann; Reiner Benecke; Stefan Teipel; Stefan Vielhaber; Johannes Prudlo
Journal:  J Neurol       Date:  2013-08-31       Impact factor: 4.849

2.  A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.

Authors:  Zachary Macchi; Yunxia Wang; Dan Moore; Jonathan Katz; David Saperstein; David Walk; Ericka Simpson; Angela Genge; Tulio Bertorini; J Americo Fernandes; Andrea Swenson; Lauren Elman; Mazen Dimachkie; Laura Herbelin; Joann Miller; Jianghua Lu; Heather Wilkins; Russell H Swerdlow; Jeffrey Statland; Richard Barohn
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-04-02       Impact factor: 4.092

3.  A plug-and-play brain-computer interface to operate commercial assistive technology.

Authors:  David E Thompson; Kirsten L Gruis; Jane E Huggins
Journal:  Disabil Rehabil Assist Technol       Date:  2013-04-16

4.  A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene.

Authors:  Jake Plewa; Abhilasha Surampalli; Marie Wencel; Merit Milad; Sandra Donkervoort; Vincent J Caiozzo; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Neuromuscul Disord       Date:  2018-06-27       Impact factor: 4.296

Review 5.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

6.  The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Michael E Bozik; Evan W Ingersoll; Robert Miller; Hiroshi Mitsumoto; Jeremy Shefner; Dan H Moore; David Schoenfeld; James L Mather; Donald Archibald; Mary Sullivan; Craig Amburgey; Juliet Moritz; Valentin K Gribkoff
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

7.  Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.

Authors:  Daichi Yokoi; Naoki Atsuta; Hazuki Watanabe; Ryoichi Nakamura; Akihiro Hirakawa; Mizuki Ito; Hirohisa Watanabe; Masahisa Katsuno; Yuishin Izumi; Mitsuya Morita; Akira Taniguchi; Masaya Oda; Koji Abe; Kouichi Mizoguchi; Osamu Kano; Satoshi Kuwabara; Ryuji Kaji; Gen Sobue
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

8.  What would brain-computer interface users want? Opinions and priorities of potential users with amyotrophic lateral sclerosis.

Authors:  Jane E Huggins; Patricia A Wren; Kirsten L Gruis
Journal:  Amyotroph Lateral Scler       Date:  2011-05-02

9.  Speech Movement Measures as Markers of Bulbar Disease in Amyotrophic Lateral Sclerosis.

Authors:  Sanjana Shellikeri; Jordan R Green; Madhura Kulkarni; Panying Rong; Rosemary Martino; Lorne Zinman; Yana Yunusova
Journal:  J Speech Lang Hear Res       Date:  2016-10-01       Impact factor: 2.297

10.  [Elective termination of respiratory therapy in amyotrophic lateral sclerosis].

Authors:  T Meyer; J S Dullinger; C Münch; J-P Keil; E Hempel; S Rosseau; N Borisow; P Linke
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.